Serving you RX Add 2 stelara biosimilars to help patients save costs
Serve You Rx, a pharmacy welfare manager, has added two recently approved biosimilars to Stelara's formula, the company announced Thursday.
Services in Milwaukee, Wisconsin You RX is an independent PBM Services Insurance Broker, Consultant, Third Party Administrator and its employer clients.
Two biosimilars it adds to its formula are Otulfi and Yesintek, which are used to treat patients with Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. Biosimilar is a drug that is very similar to the brand name Biomedicine, but is much cheaper. According to your RX CEO Justin Jasniewski, Stelara is about $20,000 a month, but the company will be able to help customers save about 96% of OTULFI with Otulfi, while YesIntek is about 90%.
Traditionally, even with low-cost biosimilars, PBM will still cover branded drugs, resulting in much greater payments for patients. But the practice of serving you RX is different.
“One of the things we did was that we created a new formula for us, called the Biosimilar Advantage Formula, which did not include high-cost reference products,” Jasniewski said in an interview. “Essentially, patients must first take lower biosimilars because it's like taking generics in most cases, they are basically the same clinically.”
Otulfi will be distributed exclusively through the Mark Cuban Cost Plus Drug Company. Cost Plus Drugs is a prescription drug company that cuts down on pharmacy middlemen and negotiates directly with drug manufacturers for cheaper prices.
Yesintek will be available on Serve You RX's professional pharmacy network powered by Waltz Health. Waltz Health offers a market called Waltz Connect, specialty pharmacies compete in quality, clinical outcomes and prices. In April, the two companies announced a partnership that provides you with RX customers’ access to Waltz Connect. When submitting professional prescriptions for members, the platform will redirect them to the most suitable pharmacy based on member benefits design, price, turnaround time, achieve accuracy, membership experience and compliance rates.
Mark Thierer, co-founder and CEO of Waltz Health, noted that the companies plan to expand to more biosimilars in the future.
“This biosimilar is really just the beginning,” he said in an interview. “You'll see Waltz delivering a smart route for many high-cost specialty drugs. This is what we expect Justin and our other customers to use it from cancer care to GLP-1. It's a long list, and it can save a lot of supply chains by collapsed chains and make it easier for patients to pair with these drugs.”
GoodRX also launched a biosimilar program. For example, last year it partnered with Boehringer Ingelheim to offer its Humira Biosimaliler exclusive cash price of $550 per two packs.
Photo: Cagkansayin, Getty Images
